Regen Biopharma Stock Current Valuation
| RGBPP Stock | USD 0.08 0.02 19.60% |
Valuation analysis of Regen BioPharma helps investors to measure Regen BioPharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Regen BioPharma's price fluctuation is out of control at this time. Calculation of the real value of Regen BioPharma is based on 3 months time horizon. Increasing Regen BioPharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Regen BioPharma's intrinsic value may or may not be the same as its current market price of 0.08, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0804 | Real 0.0772 | Hype 0.08 |
The intrinsic value of Regen BioPharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Regen BioPharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Regen BioPharma helps investors to forecast how Regen pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Regen BioPharma more accurately as focusing exclusively on Regen BioPharma's fundamentals will not take into account other important factors: Regen BioPharma Company Current Valuation Analysis
Regen BioPharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Regen BioPharma Current Valuation | 304.65 M |
Most of Regen BioPharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regen BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Regen BioPharma has a Current Valuation of 304.65 M. This is 97.88% lower than that of the Healthcare sector and 93.44% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 98.17% higher than that of the company.
Regen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regen BioPharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Regen BioPharma could also be used in its relative valuation, which is a method of valuing Regen BioPharma by comparing valuation metrics of similar companies.Regen BioPharma is currently under evaluation in current valuation category among its peers.
Regen Fundamentals
| Return On Asset | -0.76 | |||
| Profit Margin | 6.09 % | |||
| Operating Margin | (2.96) % | |||
| Current Valuation | 304.65 M | |||
| Shares Outstanding | 158.73 M | |||
| Shares Owned By Insiders | 54.77 % | |||
| Price To Earning | (0.88) X | |||
| Price To Sales | 4.60 X | |||
| Revenue | 235.52 K | |||
| Gross Profit | 235.52 K | |||
| EBITDA | 2.65 M | |||
| Net Income | 2.44 M | |||
| Cash And Equivalents | 110.99 K | |||
| Total Debt | 1.58 M | |||
| Current Ratio | 0.05 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (606.92 K) | |||
| Earnings Per Share | (0.02) X | |||
| Beta | 3.36 | |||
| Market Capitalization | 335.96 K | |||
| Total Asset | 559 K | |||
| Z Score | 13.2 | |||
| Net Asset | 559 K |
About Regen BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regen BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regen BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regen BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Regen BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regen BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regen BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Regen Pink Sheet
The ability to find closely correlated positions to Regen BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regen BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regen BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regen BioPharma to buy it.
The correlation of Regen BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regen BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regen BioPharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regen BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Regen Pink Sheet Analysis
When running Regen BioPharma's price analysis, check to measure Regen BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regen BioPharma is operating at the current time. Most of Regen BioPharma's value examination focuses on studying past and present price action to predict the probability of Regen BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regen BioPharma's price. Additionally, you may evaluate how the addition of Regen BioPharma to your portfolios can decrease your overall portfolio volatility.